Stephen L. George

Generating author description...

All published works

Action	Title	Year	Authors
+	Assessment of treatment effect heterogeneity for multiregional randomized clinical trials	2024	Haotian Zhuang Xiaofei Wang Stephen L. George
+	Futility monitoring for randomized clinical trials with non-proportional hazards: An optimal conditional power approach	2023	Xiaofei Wang Stephen L. George
+	Commentary on Harun et al.: The use of historical controls in randomized clinical trials	2023	Stephen L. George
+ PDF Chat	Design and analysis of biomarker-integrated clinical trials with adaptive threshold detection and flexible patient enrichment	2020	Ting Wang Xiaofei Wang Stephen L. George Haibo Zhou
+	A signature enrichment design with Bayesian adaptive randomization	2020	Fang Xia Stephen L. George Jing Ning Liang Li Xuelin Huang
+ PDF Chat	Bias-adjusted Kaplan–Meier survival curves for marginal treatment effect in observational studies	2019	Xiaofei Wang Fangfang Bai Herbert Pang Stephen L. George
+	Enriched Biomarker‐Driven Clinical Trials	2019	Xiaofei Wang Jianwen Cai Stephen L. George
+ PDF Chat	Auxiliary variable–enriched biomarker‐stratified design	2018	Ting Wang Xiaofei Wang Haibo Zhou Jianwen Cai Stephen L. George
+ PDF Chat	On Enrichment Strategies for Biomarker Stratified Clinical Trials	2017	Xiaofei Wang Jingzhu Zhou Ting Wang Stephen L. George
+ PDF Chat	Time‐dependent classification accuracy curve under marker‐dependent sampling	2016	Zhaoyin Zhu Xiaofei Wang Paramita Saha‐Chaudhuri Andrzej S. Kosinski Stephen L. George
+	A Multi-State Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression	2016	Fang Xia Stephen L. George Xiaofei Wang
+	A Multi-State Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression	2016	Fang Xia Stephen L. George Xiaofei Wang
+ PDF Chat	Problematic trial detection in ClinicalTrials.gov	2015	Chris Hartgerink Stephen L. George
+ PDF Chat	A Multi-State Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression	2015	Fang Xia Stephen L. George Xiaofei Wang
+	A Multi-state Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression	2015	M.S. Fang Xia Stephen L. George Xiaofei Wang
+ PDF Chat	Estimation of AUC or Partial AUC Under Test-Result-Dependent Sampling	2012	Xiaofei Wang Junling Ma Stephen L. George Haibo Zhou
+ PDF Chat	ROC curve estimation under test-result-dependent sampling	2012	Xiangyu Wang JinHua Ma Stephen L. George
+	Targeted Clinical Trials	2011	Stephen L. George Xiaofei Wang
+ PDF Chat	Multiple testing of treatment‐effect‐modifying biomarkers in a randomized clinical trial with a survival endpoint	2011	Stefan Michiels Richard F. Potthoff Stephen L. George
+ PDF Chat	Clinical Trials Data Collection: When Less Is More	2010	Daniel J. Sargent Stephen L. George
+ PDF Chat	A permutation-based multiple testing method for time-course microarray experiments	2009	Insuk Sohn Kouros Owzar Stephen L. George Sujong Kim Sin‐Ho Jung
+ PDF Chat	Sample size calculation for microarray experiments with blocked one-way design	2009	Sin‐Ho Jung Insuk Sohn Stephen L. George Liping Feng Phyllis C. Leppert
+ PDF Chat	Between-Arm Comparisons in Randomized Phase II Trials	2009	Sin‐Ho Jung Stephen L. George
+ PDF Chat	Flexible Phase I Clinical Trials: Allowing for Nonbinary Toxicity Response and Removal of Other Common Limitations	2009	Richard F. Potthoff Stephen L. George
+ PDF Chat	Statistical Issues in Translational Cancer Research	2008	Stephen L. George
+	Design of Clinical Trials of Targeted Therapy	2007	Stephen L. George
+ PDF Chat	Randomized Clinical Trial Design for Assessing Noninferiority When Superiority Is Expected	2007	Boris Freidlin Edward L. Korn Stephen L. George Robert J. Gray
+	Phase I Clinical Trials With Non-Binary Toxicity Response	2007	Richard F. Potthoff Stephen L. George
+	<i>p</i>-Value Calculation for Multistage Phase II Cancer Clinical Trials	2006	Sin‐Ho Jung Kouros Owzar Stephen L. George Taiyeong Lee
+	Rejoinder	2006	Sin‐Ho Jung Kouros Owzar Stephen L. George Taiyeong Lee
+	Processes to Activate Phase III Clinical Trials in a Cooperative Oncology Group: The Case of Cancer and Leukemia Group B	2006	David M. Dilts Alan B. Sandler Matthew J. Baker Steven K. Cheng Stephen L. George Kathleen S. Karas Stephen McGuire Gourija S. Menon Jason Reusch Debbie Sawyer
+	Controversies in the Early Reporting of a Clinical Trial in Early Breast Cancer	2006	Stephen L. George Mark R. Green
+	A general formulation for a one-sided group sequential design	2005	Barry Kurt Moser Stephen L. George
+	Sample Size Calculation for Simulation-Based Multiple-Testing Procedures	2005	Heejung Bang Sin‐Ho Jung Stephen L. George
+	A multiple testing procedure to associate gene expression levels with survival	2005	Sin‐Ho Jung Kouros Owzar Stephen L. George
+	Strength of accumulating evidence and data monitoring committee decision making	2004	Stephen L. George Boris Freidlin Edward L. Korn
+ PDF Chat	Managing Accrual in Cooperative Group Clinical Trials	2004	Todd L. Demmy Joyce M. Yasko Deborah Collyar Mira L. Katz Carol Krasnov Margaret J. Borwhat Anne Battershell Stephen L. George
+	Fulfillment of the uncertainty principle in cancer clinical trials	2004	Steven Joffe David P. Harrington Stephen L. George Ezekiel J. Emanuel L. Budzinski Jane C. Weeks
+	Fulfillment of the uncertainty principle in cancer clinical trials	2004	Steven Joffe David P. Harrington Stephen L. George Ezekiel J. Emanuel L. Budzinski J. C. Weeks
+	Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?	2004	Susan S. Ellenberg Stephen L. George
+	Data monitoring and large apparent treatment effects	2004	Edward L. Korn Boris Freidlin Stephen L. George
+	Admissible two‐stage designs for phase II cancer clinical trials	2004	Sin‐Ho Jung Taiyeong Lee KyungMann Kim Stephen L. George
+ PDF Chat	Selection Bias, Phase II Trials, and the FDA Accelerated Approval Process	2003	Stephen L. George
+	An Introduction to Randomized Controlled Clinical Trials. J. N. S. Matthews, Arnold, London, U.K., 2000. Number of pages: xiv + 189. Price: £19.99. ISBN 0‐340‐761431	2001	Stephen L. George
+	Detecting treatment‐by‐centre interaction in multi‐centre clinical trials	2001	Richard F. Potthoff Bercedis L. Peterson Stephen L. George
+	Detecting treatment-by-centre interaction in multi-centre clinical trials	2001	Richard F. Potthoff B. Peterson Stephen L. George
+	Fraud in Medical Research	2000	Jonas Ranstam Marc Buyse Stephen L. George Stephen Evans Nancy L. Geller Bruno Scherrer Emmanuel Lesaffre Gordon Murray Lutz Edler Jane L. Hutton
+	Surrogate Endpoints in Cancer Clinical Trials	2000	Stephen L. George
+ PDF Chat	The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials	1999	Marc Buyse Stephen L. George Stephen Evans Nancy L. Geller Jonas Ranstam Bruno Scherrer Emmanuel Lesaffre Gordon Murray Lutz Edler Jane L. Hutton
+	Data Monitoring Committees and Interim Monitoring Guidelines	1999	Boris Freidlin Edward L. Korn Stephen L. George
+	Statistical reviewing policies of medical journals	1998	Steven N. Goodman Douglas G. Altman Stephen L. George
+	Reducing patient eligibility criteria in cancer clinical trials.	1996	Stephen L. George
+	Stopping a clinical trial early: Frequentist and bayesian approaches applied to a CALGB trial in non‐small‐cell lung cancer	1994	Stephen L. George Chengchang Li Donald A. Berry Mark R. Green
+	Discussion of ‘sequential methods based on the boundaries approach for the clinical comparison of survival times’	1994	Stephen L. George
+	The case against independent monitoring committees	1994	David Harrington John J. Crowley Stephen L. George Thomas F. Pajak Carol Redmond Sam Wieand
+	Statistical Considerations and Modeling of Clinical Utility of Tumor Markers	1994	Stephen L. George
+	Sample size requirements and length of study for testing interaction in a 1 × k factorial design when time-to-failure is the outcome	1993	Bercedis L. Peterson Stephen L. George
+	A survey of monitoring practices in cancer clinical trials	1993	Stephen L. George
+	Quantitative estimation of the thermal dose-modifying factor for cis-diamminedichloroplatinum (CDDP) in tumour-bearing dogs	1992	Rodney L. Page Donald Ε. Thrall Stephen L. George G. Sylvester Price Greta L. Heidner Margaret C. McEntee Carol Novotney Marlene Hauck Mark W. Dewhirst
+	The bootstrap and identification of prognostic factors via cox's proportional hazards regression model	1985	Chen‐Hsin Chen Stephen L. George
+	Replicated Paired Comparisons between Two Objects: The (k,r)-Series	1974	Stephen L. George
+	Planning the size and duration of a clinical trial studying the time to some critical event	1974	Stephen L. George M. M. Desu
+	A First Course in Statistics	1972	Stephen L. George
+	A First Course in Statistics	1972	Stephen L. George F. N. David
+	Evaluation of empirical Bayes estimators for small numbers of past samples	1971	Stephen L. George

Common Coauthors

Coauthor	Papers Together
Xiaofei Wang	13
Sin‐Ho Jung	8
Richard F. Potthoff	5
Edward L. Korn	4
Fang Xia	4
Boris Freidlin	4
Kouros Owzar	4
Haibo Zhou	3
Ting Wang	3
Taiyeong Lee	3
Jane L. Hutton	2
Bercedis L. Peterson	2
Gordon Murray	2
Mark R. Green	2
Marc Buyse	2
Jianwen Cai	2
Steven Joffe	2
Peter A. Lachenbruch	2
Emmanuel Lesaffre	2
Nancy L. Geller	2
Bruno Scherrer	2
Jonas Ranstam	2
L. Budzinski	2
David P. Harrington	2
Theodore Colton	2
Insuk Sohn	2
Stephen Evans	2
Lutz Edler	2
Xuelin Huang	1
Steven N. Goodman	1
Margaret J. Borwhat	1
Todd L. Demmy	1
Stefan Michiels	1
Heejung Bang	1
Amy Wu	1
Kai Zhou	1
Kathleen S. Karas	1
Mark W. Dewhirst	1
Donald A. Berry	1
Carol Novotney	1
Chen‐Hsin Chen	1
Maren Scoggins	1
F. N. David	1
Robert J. Gray	1
Marlene Hauck	1
Deborah Collyar	1
Mira L. Katz	1
Herbert Pang	1
Rodney L. Page	1
Stephen McGuire	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+ PDF Chat	Randomized Clinical Trials With Biomarkers: Design Issues	2010	Boris Freidlin Lisa M. McShane Edward L. Korn	6
+ PDF Chat	Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges	2009	Sumithra J. Mandrekar Daniel J. Sargent	5
+ PDF Chat	Estimation of AUC or Partial AUC Under Test-Result-Dependent Sampling	2012	Xiaofei Wang Junling Ma Stephen L. George Haibo Zhou	5
+	Sample size requirements and length of study for testing interaction in a 1 × k factorial design when time-to-failure is the outcome	1993	Bercedis L. Peterson Stephen L. George	5
+	Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset	2007	Sue‐Jane Wang Robert T. O’Neill Hung Hung	5
+ PDF Chat	Design and Inference for Cancer Biomarker Study with an Outcome and Auxiliary‐Dependent Subsampling	2009	Xiaofei Wang Haibo Zhou	5
+	Planning the size and duration of a clinical trial studying the time to some critical event	1974	Stephen L. George M. M. Desu	5
+	Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials	2005	Daniel J. Sargent Barbara A. Conley Carmen J. Allegra Laurence Collette	5
+ PDF Chat	Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials	2004	Richard Simon Aboubakar Maitournam	5
+	The asymptotic properties of nonparametric tests for comparing survival distributions	1981	David Schoenfeld	4
+ PDF Chat	Improving cost‐effectiveness of epidemiological studies via designed missingness strategies	2010	Warren Strauss Louise Ryan Michele Morara Nicole Iroz‐Elardo Mark D. Davis Matthew Cupp Marcia Nishioka James J. Quackenboss Warren Galke Halûk Özkaynak	4
+	Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.	1994	Michael A. Martin Peter H. Westfall S. Stanley Young	4
+ PDF Chat	On Enrichment Strategies for Biomarker Stratified Clinical Trials	2017	Xiaofei Wang Jingzhu Zhou Ting Wang Stephen L. George	4
+ PDF Chat	ROC curve estimation under test-result-dependent sampling	2012	Xiangyu Wang JinHua Ma Stephen L. George	4
+	Monitoring clinical trials: Conditional or predictive power?	1986	David J. Spiegelhalter Laurence S. Freedman Patrick R. Blackburn	4
+ PDF Chat	The Use of Genomics in Clinical Trial Design	2008	Richard Simon	4
+ PDF Chat	Sample size calculation for multiple testing in microarray data analysis	2004	Sin‐Ho Jung Heejung Bang S. Stanley Young	4
+ PDF Chat	Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients	2005	Boris Freidlin Richard Simon	4
+	Optimal design for epidemiological studies subject to designed missingness	2007	Michele Morara Louise Ryan E. Andrés Houseman Warren Strauss	4
+	Data Monitoring Committees and Interim Monitoring Guidelines	1999	Boris Freidlin Edward L. Korn Stephen L. George	4
+ PDF Chat	On the efficiency of targeted clinical trials	2004	A. Maitournam Richard Simon	4
+	Design and Analysis of Phase I Clinical Trials	1989	Barry E. Storer	3
+	Enrichment design with patient population augmentation	2015	Bo Yang Yijie Zhou Lanju Zhang Lu Cui	3
+	Biased sampling designs to improve research efficiency: Factors influencing pulmonary function over time in children with asthma	2015	Jonathan S. Schildcrout Paul J. Rathouz Leila R. Zelnick Shawn Garbett Patrick J. Heagerty	3
+	Designs for Group Sequential Phase II Clinical Trials	1987	M N Chang Terry M. Therneau H. Samuel Wieand S. Stephen	3
+ PDF Chat	Optimal two-stage designs for phase II clinical trials	1989	Richard Simon	3
+	Repeated Significance Tests on Accumulating Data	1969	P. Armitage C. K. McPherson Beverley Charles Rowe	3
+	Comparison of Statistical Analysis Plans in Randomize-All Phase III Trials with a Predictive Biomarker	2014	Shigeyuki Matsui Yuki Choai Takahiro Nonaka	3
+ PDF Chat	Using Bayesian modeling in frequentist adaptive enrichment designs	2017	Noah Simon Richard Simon	3
+	A Semiparametric Empirical Likelihood Method for Biased Sampling Schemes with Auxiliary Covariates	2006	Xiaofei Wang Haibo Zhou	3
+	Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework	2001	Arthur J. Atkinson Wayne A. Colburn Victor G. DeGruttola David L. DeMets Gregory J. Downing Daniel F. Hoth John A. Oates Carl C. Peck Robert T. Schooley Bert Spilker	3
+	Group sequential methods in the design and analysis of clinical trials	1977	Stuart J. Pocock	3
+ PDF Chat	Statistical Issues in Translational Cancer Research	2008	Stephen L. George	3
+ PDF Chat	An Approach to Evaluating and Comparing Biomarkers for Patient Treatment Selection	2014	Holly Janes Marshall Brown Ying Huang Margaret S. Pepe	3
+	Group Sequential Methods with Applications to Clinical Trials	1999	Christopher Jennison Bruce W. Turnbull	3
+ PDF Chat	Adaptive enrichment designs for clinical trials	2013	Noah Simon Richard H. Simon	3
+	On the estimation of the binomial probability in multistage clinical trials	2004	Sin‐Ho Jung Kyung Mann Kim	3
+	A Semiparametric Empirical Likelihood Method for Data from an Outcome-Dependent Sampling Scheme with a Continuous Outcome	2002	Haibo Zhou Mark A. Weaver Jing Qin Matthew P. Longnecker M. C. Wang	3
+	Testing for Qualitative Interactions between Treatment Effects and Patient Subsets	1985	Mitchell H. Gail Richard Simon	3
+	Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing	1995	Yoav Benjamini Yosef Hochberg	3
+	Graphical Search for Two-Stage Designs for Phase II Clinical Trials	2001	Sin‐Ho Jung Mark Carey Kyung Mann Kim	3
+	Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment	1993	Yogendra P. Chaubey Peter H. Westfall Stefano Young	3
+ PDF Chat	A Direct Approach to False Discovery Rates	2002	John D. Storey	3
+	Regression modelling strategies for improved prognostic prediction	1984	Frank E. Harrell Kerry L. Lee Robert M. Califf David B. Pryor Robert A. Rosati	3
+	Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer	1990	John O’Quigley Margaret S. Pepe Lloyd D. Fisher	3
+	A Multiple Testing Procedure for Clinical Trials	1979	Peter C. O’Brien Thomas R. Fleming	3
+ PDF Chat	Empirical Likelihood and General Estimating Equations	1994	Qin Jin Jerry Lawless	3
+	A comment on futility monitoring	2002	Boris Freidlin Edward L. Korn	3
+ PDF Chat	Measuring the Performance of Markers for Guiding Treatment Decisions	2011	Holly Janes Margaret S. Pepe Patrick M. Bossuyt William E. Barlow	3
+	The Statistical Evaluation of Medical Tests for Classification and Prediction	2005	Margaret S. Pepe	2